First-line pembrolizumab for advanced non-clear cell renal cell carcinoma

Prof. David McDermott

The multinational phase 2 study KEYNOTE-427 (cohort A) found promising antitumor activity of first-line pembrolizumab monotherapy for advanced non-clear cell renal cell carcinoma.